Novartis extends transparency initiative to patient-level data

Novartis has announced additional steps to further its transparency around clinical trial data. Researchers can also now request access to patient level data on newly approved innovative medicines in 2014 through the ideaPoint portal.

Novartis has long supported data transparency and was the first company to publish positive and negative study results of its innovative medicines within one year of the study completion further enabling clinical research while protecting patient privacy.

To date, Novartis has registered 2,720 trials on ClinicalTrials.gov and published 559 trial results on the same site as well as 1,777 clinical study summaries (known as “redacted clinical study reports”).